Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 38:436-442
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanek, B.
Right arrow Articles by Pacher, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanek, B.
Right arrow Articles by Pacher, R.

CLINICAL STUDY

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

Brigitte Stanek, MDa, Bernhard Frey, MDa, Martin Hülsmann, MDa, Rudolf Berger, MDa, Barbara Sturm, MDa, Jeanette Strametz-Juranek, MDa, Jutta Bergler-Klein, MDa, Petra Mosera, Anja Bojic, MDa, Engelber Hartter, MD, PhDa and Richard Pacher, MDa

a Department of Cardiology, Ludwig Boltzmann Institute of Experimental Endocrinology and Ludwig Boltzmann Institute of Cardiovascular Research, University of Vienna, Vienna, Austria

Manuscript received November 15, 2000; revised manuscript received April 13, 2001, accepted April 26, 2001.

Reprint requests and correspondence: Dr. Brigitte Stanek, Department of Cardiology, University of Vienna, A-1090 Vienna, Austria
edithtanzl{at}akh-wien.ac.at

OBJECTIVES

The study assessed the relative predictive potency of neurohumoral factors in patients with advanced left ventricular (LV) dysfunction during neurohumoral blocking therapy.

BACKGROUND

The course of heart failure is characterized by progressive LV deterioration associated with an increase in cardiac (natriuretic peptides) and predominantly extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels.

METHODS

Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo. After the double-blind study phase, patients were followed up to four years. Stepwise multivariate regression analyses were performed with 10 variables (age, etiology, LVEF, symptom class, atenolol/placebo, norepinephrine, big ET, log aminoterminal atrial natriuretic peptide, log aminoterminal B-type natriuretic peptide [N-BNP] and log B-type natriuretic peptide [BNP]). During the study, the last values prior to patient death were used, and in survivors the last hormone level, New York Heart Association class and LVEF at month 24 were used.

RESULTS

Thirty-one patients died from a cardiovascular cause during follow-up. At baseline, log BNP plasma level (x2 = 13.9, p = 0.0002), treatment allocation (x2 = 9.5, p = 0.002) and LVEF (x2 = 5.6, p = 0.017) were independently related to mortality. During the study, log BNP plasma level (x2 = 21.3, p = 0.0001) remained the strongest predictive marker, with LVEF (x2 = 11.2, p = 0.0008) log N-BNP plasma level (x2 = 8.9, p = 0.0027) and treatment allocation (x2 = 6.4, p = 0.0109) providing additional independent information.

CONCLUSIONS

In patients with advanced LV dysfunction receiving high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy BNP and N-BNP plasma levels are both independently related to mortality. This observation highlights the importance of these hormones and implies that they will likely emerge as a very useful blood test for detection of the progression of heart failure, even in the face of neurohumoral blocking therapy.

Abbreviations and Acronyms
  ANOVA = analysis of variance
  ANP = atrial natriuretic peptide
  BNP = B-type natriuretic peptide
  ELISA = enzyme-linked immunosorbent assay
  ET = endothelin
  LV = left ventricle, ventricular
  LVEF = left ventricular ejection fraction
  N-ANP = aminoterminal atrial natriuretic peptide
  N-BNP = aminoterminal B-type natriuretic peptide
  NE = norepinephrine
  NYHA = New York Heart Association




This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
B. W.L. De Boeck, A. J. Teske, M. Meine, G. E. Leenders, M. J. Cramer, F. W. Prinzen, and P. A. Doevendans
Septal rebound stretch reflects the functional substrate to cardiac resynchronization therapy and predicts volumetric and neurohormonal response
Eur J Heart Fail, September 1, 2009; 11(9): 863 - 871.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
O. Tsukamoto, M. Fujita, M. Kato, S. Yamazaki, Y. Asano, A. Ogai, H. Okazaki, M. Asai, Y. Nagamachi, N. Maeda, et al.
Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2070 - 2077.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Yasuno, S. Usami, K. Kuwahara, M. Nakanishi, Y. Arai, H. Kinoshita, Y. Nakagawa, M. Fujiwara, M. Murakami, K. Ueshima, et al.
Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1804 - H1810.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
L. Frankenstein, C. Zugck, D. Schellberg, M. Nelles, H. Froehlich, H. Katus, and A. Remppis
Prevalence and prognostic significance of adrenergic escape during chronic {beta}-blocker therapy in chronic heart failure
Eur J Heart Fail, February 1, 2009; 11(2): 178 - 184.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J P Kaski, M T Tome-Esteban, S Mead-Regan, A Pantazis, J Marek, J E Deanfield, W J McKenna, and P M Elliott
B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy
Heart, October 1, 2008; 94(10): 1307 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
D. Moertl, A. Hammer, M. Huelsmann, R. Pacher, and R. Berger
Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients
Eur J Heart Fail, April 1, 2008; 10(4): 404 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
L. G. Olsson, K. Swedberg, J. G.F. Cleland, P. A. Spark, M. Komajda, M. Metra, C. Torp-Pedersen, W. J. Remme, A. Scherhag, P. Poole-Wilson, et al.
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial
Eur J Heart Fail, August 1, 2007; 9(8): 795 - 801.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Bergler-Klein, G. Mundigler, P. Pibarot, I. G. Burwash, J. G. Dumesnil, C. Blais, C. Fuchs, D. Mohty, R. S. Beanlands, Z. Hachicha, et al.
B-Type Natriuretic Peptide in Low-Flow, Low-Gradient Aortic Stenosis: Relationship to Hemodynamics and Clinical Outcome: Results From the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) Study
Circulation, June 5, 2007; 115(22): 2848 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J. F. Aupetit, M. C. Aumont, M. Galinier, J. C. Eicher, et al.
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure: The STARS-BNP Multicenter Study
J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1733 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
C. Berry, N. Murphy, G. De Vito, S. Galloway, A. Seed, C. Fisher, N. Sattar, P. Vallance, W. S. Hillis, and J. McMurray
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker
Eur J Heart Fail, April 1, 2007; 9(4): 429 - 434.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al.
Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Circulation, February 6, 2007; 115(5): 658 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. V. Pitzalis, M. Iacoviello, F. Di Serio, R. Romito, P. Guida, E. De Tommasi, G. Luzzi, M. Anaclerio, L. Varraso, C. Forleo, et al.
Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy
Eur J Heart Fail, August 1, 2006; 8(5): 509 - 514.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, F. Boomsma, and D. J. Van Veldhuisen
Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP
Europace, July 1, 2006; 8(7): 482 - 487.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
B S Rana, J I Davies, M M Band, S D Pringle, A Morris, and A D Struthers
B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes
Heart, July 1, 2006; 92(7): 916 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton
Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure
Circulation, February 21, 2006; 113(7): 977 - 985.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Nakanishi, Y. Saito, I. Kishimoto, M. Harada, K. Kuwahara, N. Takahashi, R. Kawakami, Y. Nakagawa, K. Tanimoto, S. Yasuno, et al.
Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice
Hypertension, August 1, 2005; 46(2): 441 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
R. Valle, N. Aspromonte, S. Barro, C. Canali, E. Carbonieri, V. Ceci, M. Chinellato, G. Gallo, P. Giovinazzo, R. Ricci, et al.
The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure
Eur J Heart Fail, June 1, 2005; 7(4): 542 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
S. W. Kong, N. Bodyak, P. Yue, Z. Liu, J. Brown, S. Izumo, and P. M. Kang
Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats
Physiol Genomics, March 21, 2005; 21(1): 34 - 42.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J. A Doust, E. Pietrzak, A. Dobson, and P. Glasziou
How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review
BMJ, March 19, 2005; 330(7492): 625.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. G. Williams, L. L. Ng, R. J. O'Brien, S. Taylor, D. J. Wright, and L.-B. Tan
Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study
Eur J Heart Fail, December 1, 2004; 6(7): 891 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Jernberg, S. James, B. Lindahl, N. Johnston, M. Stridsberg, P. Venge, and L. Wallentin
Natriuretic peptides in unstable coronary artery disease
Eur. Heart J., September 1, 2004; 25(17): 1486 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi
Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 38 - 43.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Bergler-Klein, U. Klaar, M. Heger, R. Rosenhek, G. Mundigler, H. Gabriel, T. Binder, R. Pacher, G. Maurer, and H. Baumgartner
Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis
Circulation, May 18, 2004; 109(19): 2302 - 2308.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. de Groote, J. Dagorn, B. Soudan, N. Lamblin, E. McFadden, and C. Bauters
B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure
J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1584 - 1589.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. P. Goetze, W. Yongzhong, J. F Rehfeld, E. Jorgensen, and J. Kastrup
Coronary angiography transiently increases plasma pro-B-type natriuretic peptide
Eur. Heart J., May 1, 2004; 25(9): 759 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Bayes-Genis, M. Santalo-Bel, E. Zapico-Muniz, L. Lopez, C. Cotes, J. Bellido, R. Leta, P. Casan, and J. Ordonez-Llanos
N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction
Eur J Heart Fail, March 15, 2004; 6(3): 301 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
P. Bettencourt
NT-proBNP and BNP: biomarkers for heart failure management
Eur J Heart Fail, March 15, 2004; 6(3): 359 - 363.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Kyuma, T. Nakata, A. Hashimoto, K. Nagao, H. Sasao, T. Takahashi, K. Tsuchihashi, and K. Shimamoto
Incremental Prognostic Implications of Brain Natriuretic Peptide, Cardiac Sympathetic Nerve Innervation, and Noncardiac Disorders in Patients with Heart Failure
J. Nucl. Med., February 1, 2004; 45(2): 155 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Hasegawa, H. Kusuoka, K. Maruyama, T. Nishimura, M. Hori, and J. Hatazawa
Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers
J. Am. Coll. Cardiol., January 21, 2004; 43(2): 224 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Clerico and M. Emdin
Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review
Clin. Chem., January 1, 2004; 50(1): 33 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al.
Clinical applications of B-type natriuretic peptide (BNP) testing
Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R.S. Gardner, F. Ozalp, A.J. Murday, S.D. Robb, and T.A. McDonagh
N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure
Eur. Heart J., October 1, 2003; 24(19): 1735 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
H. Ruskoaho
Cardiac Hormones as Diagnostic Tools in Heart Failure
Endocr. Rev., June 1, 2003; 24(3): 341 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Mueller, A. Gegenhuber, W. Poelz, and M. Haltmayer
Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease
Clin. Chem., June 1, 2003; 49(6): 976 - 979.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Hulsmann, R. Berger, B. Sturm, A. Bojic, W. Woloszczuk, J. Bergler-Klein, and R. Pacher
Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure
Eur. Heart J., June 1, 2002; 23(11): 886 - 891.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, and R. Pacher
B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure
Circulation, May 21, 2002; 105(20): 2392 - 2397.
[Abstract] [Full Text] [PDF]

Home page
 Am J Crit CareHome page
L. G. Futterman and L. Lemberg
Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A
Am. J. Crit. Care., March 1, 2002; 11(2): 168 - 172.
[Full Text] [PDF]

Home page
 NEJMHome page
L. E. Rabbani
Acute Coronary Syndromes -- Beyond Myocyte Necrosis
N. Engl. J. Med., October 4, 2001; 345(14): 1057 - 1059.
[Full Text] [PDF]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement